Differential DNA methylation analysis of SUMF2, ADAMTS5, and PXDN provides novel insights into colorectal cancer prognosis prediction in Taiwan

Table 3 Methylation level of sulfatase modifying factor 2 and ADAM metallopeptidase with thrombospondin type 1 motif 5 in normal tissue and tumor tissue (n= 208)

	Normal			Tumor			P value
	n1	Median	mean ± SD2	n1	Median	mean ± SD2
SUMF2
CpG_1	69	0.40	0.43 ± 0.15	104	0.53	0.55 ± 0.17	< 0.001
CpG_2	70	0.56	0.56 ± 0.11	104	0.76	0.73 ± 0.13	< 0.001
CpG_3	70	0.38	0.39 ± 0.11	104	0.54	0.54 ± 0.17	< 0.001
CpG_7	48	0.64	0.64 ± 0.15	80	0.87	0.81 ± 0.20	0.001
ADAMTS5
CpG_1	66	0.06	0.08 ± 0.07	95	0.19	0.25 ± 0.20	< 0.001
CpG_2	70	0.06	0.08 ± 0.06	105	0.20	0.24 ± 0.18	< 0.001
CpG_9	69	0.06	0.07 ± 0.06	91	0.21	0.25 ± 0.18	< 0.001
CpG_10.11	69	0.08	0.10 ± 0.09	103	0.30	0.34 ± 0.22	< 0.001
CpG_12	65	0.09	0.10 ± 0.08	98	0.19	0.24 ± 0.21	0.001
CpG_13	63	0.07	0.12 ± 0.14	94	0.15	0.22 ± 0.22	0.009
CpG_14.15	71	0.32	0.33 ± 0.05	105	0.43	0.44 ± 0.11	< 0.001
CpG_16	71	0.10	0.11 ± 0.04	105	0.19	0.22 ± 0.12	< 0.001

¹The total number of colorectal cancer patients does not correspond because of missing data.

²Represent the ratio of DNA methylation.

SD: Standard deviation; SUMF2: Sulfatase modifying factor 2; ADAMTS5: ADAM metallopeptidase with thrombospondin type 1 motif 5.